Journal of Parkinsons disease and Alzheimers disease

Review Article

Critical Assessment of the Status of Biomarkers for Alzheimer’s disease

Paul L. Wood1* and Julie A. Wood2

      • 1DeBusk College of Osteopathic Medicine, Lincoln Memorial University, 6965 Cumberland Gap Parkway, Harrogate, TN37752, USA
      • 2Southwestern Behavioral Healthcare, 415 Mulberry St, Evansville, IN 47713, USA

*Address for Correspondence: Dr. Paul L. Wood, DeBusk College of Osteopathic Medicine, Lincoln Memorial University, 6965 Cumberland Gap Parkway, Harrogate, TN37752, USA, Tel: 423-869-6666; E-mail:
Citation: Wood PL, Wood JA. Critical Assessment of the Status of Biomarkers for Alzheimer’s disease. J Parkinsons Dis Alzheimer Dis. 2014;1(1): 4.
Copyright © 2014 Wood et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Journal of Parkinson’s disease and Alzheimer's disease | ISSN: 2376-922X | Volume: 1, Issue: 1
Submission: 22 August 2014 | Accepted: 30 September 2014 | Published: 03 October 2014


Objective: We undertook a critical analysis of the status of the progress in the development of biomarkers for the detection of Alzheimer’s disease (AD).

Methods: Biomarker studies involving imaging, metabolomics, lipidomics, proteomics, transcriptomics and microRNAs were assessed from publications between 2004 and 2014.

Results: Extensive efforts have been applied to the development of minimally invasive and inexpensive assays for the early detection of AD. However, the failure to replicate findings between laboratories has presented a significant challenge in validating assays for clinical use. Larger scale studies and collaborations are required to standardize sample collection and storage, analytical methodology, and to control for heterogeneity in the AD patient population.

Conclusions: Since cognitive testing cannot detect the presymptomatic stages of AD, validated biomarkers are essential for advancing both AD research and clinical practice. Despite intensive research over the last 10 years, there currently are no validated biomarkers for the early detection of AD.


The clinical diagnosis of Alzheimer’s disease (AD) involves elimination of alternate potential causes for cognitive decline, with the diagnosis ultimately requiring neuropathological confirmation at autopsy. However, current research efforts in AD have demonstrated that historical assumptions are not valid and that heterogeneity in clinically defined AD populations is more complex than was anticipated. This is best exemplified by elderly individuals who demonstrate limited cognitive deficit but at autopsy possess a neuropathology burden (plaques and tangles) that would result in a diagnosis of AD [1-5]. These individuals have been termed nondemented with AD neuropathology or NDAN [4,5]. The mirror image elderly population encompasses individuals demonstrating poor memory and executive functions, with neurodegenerative abnormalities (e.g. cortical thinning), but in the absence of amyloiddeposition [6,7].

These data clearly indicate that historical post-mortem definition of AD need reassessment and that heterogeneity in the clinically diagnosed AD patient population offers challenges to thedevelopment of ante-mortem biomarkers to detect and monitor the progress of AD and for the development of therapeutic interventions for subpopulations with different disease etiologies.

Improvements in the ability to more accurately define patient subpopulations in AD will ultimately lead to the development of therapeutic interventions and individualized patient care. This lofty goal will only be reached by integrating cognitive evaluation, imaging, and biomarkers as well as collaboration between academic researchers, government, and the pharmaceutical industry. An excellent example of this approach involved evaluation of theheterogeneity in mild cognitive impairment (MCI) subjects utilizing cognitive testing, imaging of hippocampal and ventricular volumes, imaging of white matter hyperintensities (WMH), and CSF tau and amyloid-beta (Aβ) [8].

Cognitive Testing

Dementia diagnosis in primary medical care remains a challenge despite advances in the development of brief cognitive screening instruments with decreased susceptibility to cultural and educational biases [9,10]. To increase our ability for the early detection of the disease process in AD, intense research efforts have been undertaken to characterize MCI and pre-MCI [11]. Impairment in episodic memory has been shown to be a reliable index of the likelihood ofprogression from MCI to AD [12]. Other cognitive domains that demonstrate impairments include executive function, language, attention, and visuospatial skills [11-13]. However, there is significant heterogeneity in the expression of these impairments. For example, it has recently been demonstrated that patients demonstrating greater amnestic deficits than executive dysfunction have greater odds of having hypertension and the APOEε4 allele than subjects where executive dysfunction predominates [14].

In summary, a number of new cognitive instruments are being used in AD research in combination with imaging and biomarkers. However, there remains a large divide in advancing reliable testing paradigms into primary care.


Advances in the resolution of imaging techniques have made possible a number of advances in the evaluation of brain structural changes in MCI and AD. Longitudinal MRI has demonstrated progressive brain atrophy of 1 to 3% per year in AD [15], with detection approximately 3 years prior to a clinical diagnosis of AD. Also of note is that brain atrophy is less in cognitively normal individuals (NDAN) who at autopsy demonstrate a high burden of AD pathology (Braak stage V or VI) [1]. The limitations of this imaging approach are that brain atrophy is not unique to AD, the rates of atrophy are small with large error estimates, brain shrinkage is not an early disease process,and the technology is not simple or inexpensive. Studies combining MRI volumetric data with 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scans have indicated that hypo metabolism generally precedes atrophy in MCI patients and is alsodetected in brain areas that subsequently demonstrate little atrophy [16]. As with MRI, this approach is limited by expense, availability of PET facilities, and determination of the sensitivity of this approach for early detection requires expanded investigation to larger clinical populations.

In addition to brain atrophy, diffusion tensor imaging (DTI) has detected decreased white matter integrity in MCI and AD, independent of cortical thinning [17,18]. A major issue that still remains to be resolved is the relative contributions of altered oligodendroglial function and cerebral small vessel disease to the white matter findings in AD. In the case of small vessel disease, cerebral microbleeds are evident in approximately 40% of AD patients, 24% of MCI patients, and 18% of age-matched controls [19,20]. These data clearly indicate that cerebral vessel dysfunction contributes to the heterogeneity of clinical populations utilized in the search for AD biomarkers.

Brain amyloid imaging has been made possible by the introduction of PET amyloid ligands [21]. While PET amyloid imaging has been approved by the FDA, the major concern with this biomarker relates to its specificity and therefore utility in clinical practice. There are a number of issues related to the issue of specificity. First, PET amyloid ligand imaging has shown that a significant number of cognitively normal elderly have amyloid-beta (Aβ) deposition in the brain,with deposition increasing over time [22]. Second, significant AD pathology, including extensive amyloid deposition, has been reported for a substantial number of cognitively normal elderly at autopsy [2,3]. Third, there appear to be a significant number of cognitively normal elderly which possess features of neurodegeneration (cortical atrophy and white matter lesions) but no increase in Aβdeposition as reflected by PET amyloid ligand imaging [6,23]. Fourth, large scale phase III clinical trials have revealed that 10 to 35% of clinically diagnosed AD patients have no Aβ deposition as detected by PET imaging [24]. Fifth, while amyloid lowering agents are effective in reversing pathology and cognitive decline in amyloid mouse models they all have failed in the clinic [25]. These data suggest that while PET amyloid ligand imaging may be a tool in the evaluation of AD patients, it is not a test that will stand alone without other biomarkers.


Extensive research has been directed to identify and validate cerebrospinal fluid (CSF) biomarkers of AD. The universal conclusion is that a combination of biomarkers is superior to any individual biomarker. While a number of algorithms have been proposed by various laboratories, a simple ratio of higher total tau or phosphorylated tau (p-tau) to lower amyloid-beta (Aβ42) appears to detect MCI patients who convert to AD [26]. However, it is important to remember that increased levels of tau or p-tau are a non-specific marker of neurodegeneration associated with a diversity of biological processes. Similarly, decrements in CSF Aβ42 are not specific to AD. These decrements also are found in vascular dementia, corticobasal degeneration, frontotemporal lobar degeneration, Lewy body dementia, and cerebral amyloid angiopathy [27].

Evaluation of plasma proteomics in MCI and AD is at an earlier stage of maturity. Current methodology is limited by poor reproducibility such that some proteins can be statistically different in opposite directions on replication [28,29].


Metabolomics studies have revealed potential alterations in a number of amino acids and metabolites of intermediary metabolism [30-33]. However, the failure to replicate findings between laboratories may well relate to labiality of many of these metabolites and demands further investigation.


Lipidomics studies in AD have mainly focused on glycerophospholipids and sphingolipids [34]. The most remarkable glycerophospholipid alteration involves decrements in choline and ethanolamine plasmalogens in brain [35], liver [36] and plasma [37,38] from AD patients. However, more recent evaluations of plasma [32,39] and brain [40-42] plasmalogens from MCI patients have demonstrated that alterations in these lipids do not occur early in the disease process, thereby limiting their value as ante-mortem biomarkers. Recent publication of a panel of 10 plasma lipids as a potential biomarker of antecedent memory impairment is limited by the fact that the means of all 10 lipids in the MCI groups were within the error bars of the age-matched controls [30].

Data obtained from sphingolipid metabolism in AD are more controversial. Large decrements in white matter levels of sulfatides and associated increases in ceramides have been reported as an early lipid change in AD [41]. However, replication of these studies by other laboratories has reported more modest alterations in these oligodendroglial lipids in AD brain [40-43].

Similarly analysis of plasma sphingolipids has generated variable data. While elevated ceramides have been reported for AD plasma [44], these findings were not replicated with lower levels of ceramides measured in MCI plasma [45]. Decrements in sphingomyelins also were observed in MCI [45] and AD [45] plasma but contradictory data also has been reported [38].

Other lipid biomarkers of potential interest include desmosterol and diacylglycerols (DAG). Decreased levels of desmosterolin plasma and CSF [46] in AD patients suggest that cholesterol metabolism is altered in the disease process. However, contradictory data also has been published [47].

Increases in the levels of DAG have been reported both for AD cortex [40,42,43] and plasma [38,39]. Since DAG serve as mediators of signal transduction and as precursors to diverse families of structural glycero- and glycerophospho-lipids, these findings need wider validation, particularly since increases were greatest in the plasma [39] and brains [42] of MCI patients.


Altered RNA expression in AD blood has been demonstrated for a number of genes, some overlapping with changes in AD brain [48]. These data require further validation by other groups and investigation in MCI patients to determine their possible utility as AD biomarkers.

MicroRNA (miR)

miRs are present in biofluids and offer a potential source of novel biomarkers. Recent research has demonstrated increased circulating levels of the miR-132 (miR-128, miR-132, miR-874) and miR-134 (miR-134, miR-323, miR382) families in MCI plasma [49] and AD plasma [50]. The utility of miR biomarkers requires further validation based on the complexity of miR regulatory networks with a single miR possessing hundreds of potential gene targets.


Biomarker research in dementia is moving forward at a rapid pace. With investments in standardization of methods and enlarged clinical collaborations, biomarkers of clinical utility will become available within a decade.


  1. Erten-Lyons D, WoltjerRL, Dodge H, Nixon R, Vorobik R, et al. (2009) Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 72: 354-360.
  2. Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, et al. (2011) Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol Aging 32: 2113-2122.
  3. Maarouf CL, Daugs ID, Kokjohn TA, Walker DG, Hunter JM, et al. (2011) Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One 6: e27291.
  4. Yoshioka C, Crawford JR, Bjorklund NL, Taglialatela G, Gomer RH (2012) Brain serum amyloid P levels are reduced in individuals that lack dementia while having Alzheimer's disease neuropathology. Neurochem Res 37: 795-801.
  5. Bjorklund NL, Reese LC, Sadagoparamanujam VM, Ghirardi V, Woltjer RL, et al. (2012) Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer's disease neuropathology. Mol Neurodegener 7: 23.
  6. Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, et al. (2013) Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70: 1512-1519.
  7. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, et al. (2014) Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370: 322-333.
  8. Nettiksimmons J, Decarli C, Landau S, Beckett L (2014) Biological heterogeneity in ADNI amnestic mild cognitive impairment. Alzheimers Dement 10: 511-521.
  9. Parmar J, Dobbs B, McKay R, Kirwan C, Cooper T, et al. (2014) Diagnosis and management of dementia in primary care: exploratory study. Can Fam Physician 60: 457-465.
  10. Lin JS, O'Connor E, Rossom RC, Perdue LA, Eckstrom E (2013) Screening for cognitive impairment in older adults: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 159: 601-612.
  11. deGobbi Porto FH, Spíndola L, de Oliveira MO, Figuerêdo do Vale PH, OrsiniM et al. (2013) A score based on screening tests to differentiate mild cognitive impairment from subjective memory complaints. Neurol Int 5: e16.
  12. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, et al. (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer’s Dement 7: 270-279.
  13. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269.
  14. Mez J, Cosentino S, Brickman AM, Huey ED, Manly JJ, et al. (2013) Dysexecutive versus amnestic Alzheimer disease subgroups: analysis of demographic, genetic, and vascular factors. Alzheimer Dis Assoc Disord 27: 218-225.
  15. Whitwell JL (2010) Progression of atrophy in Alzheimer's disease and related disorders. Neurotox Res 18: 339-346.
  16. KljajevicV, Grothe MJ, Ewers M, Teipel S (2014) Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer'sdisease. Neurobiol Aging 35: 1973-1981.
  17. Stricker NH, Salat DH, Foley JM, Zink TA, Kellison IL, et al. (2013) Decreased white matter integrity in neuropsychologically defined mild cognitive impairment is independent of cortical thinning. J Int Neuropsychol Soc 19: 925-937.
  18. Lim JS, Park YH, Jang J (2014) Alzheimer's Disease Neuroimaging Initiative. Differential white matter connectivity in early mild cognitive impairment according to CSF biomarkers. PLoS One 9: e91400.
  19. Yates PA, Desmond PM, Phal PM, Steward C, Szoeke C, et al. (2014) Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology 82: 1266-1267.
  20. Rincon F, Wright CB (2014) Current path physiological concepts in cerebral small vessel disease. Front Aging Neurosci 6: 24.
  21. Nasrallah I, Dubroff J (2013) An overview of PET neuroimaging. Semin Nucl Med 43: 449-461.
  22. Chételat G, La Joie R, Villain N, Perrotin A, de La Sayette V, et al. (2013) Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer'sdisease. Neuroimage Clin 2: 356-365.
  23. Knopman DS, Jack CR Jr,Wiste HJ, Weigand SD, Vemuri P, et al. (2013) Brain injury biomarkers are not dependent on β-amyloid in normal elderly.Ann Neurol 73: 472-480.
  24. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, et al. (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370: 322-333.
  25. Castello MA, Soriano S. (2013) On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis. Ageing Res Rev 13C: 10-12.
  26. Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, et al. (2014) The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean? Alzheimers Dement [Epub ahead of print].
  27. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, et al. (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78: 47-54.
  28. Liu Y, Qing H, Deng Y. (2014) Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. Int J Mol Sci 15: 7865-7882.
  29. Song F, Poljak A, Kochan NA, Raftery M, Brodaty H, et al. (2014) Plasma protein profiling of Mild Cognitive Impairment and Alzheimer'sdisease using iTRAQ quantitative proteomics. Proteome Sci 12: 5.
  30. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, et al. (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20: 415-418.
  31. Tsuruoka M, Hara J, Hirayama A, Sugimoto M, Soga T, et al. (2013) Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis 34: 2865-2872.
  32. Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC (2013) Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One 8: e63644.
  33. Ibáñez C, Simó C, Barupal DK, Fiehn O, Kivipelto M, et al. (2013) A new metabolomic workflow for early detection of Alzheimer's disease. J Chromatogr A 1302: 65-71.
  34. Wood PL (2012) Lipidomics of Alzheimer's disease: current status. Alzheimers Res Ther 4: 5.
  35. Han X (2005) Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2: 65-77.
  36. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, et al. (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One 5: e12538.
  37. 37. Wood PL, Mankidy R, Ritchie S, Heath D, Wood JA, et al. (2014) Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J Psychiatry Neurosci 35: 59-62.
  38. González-Domínguez R, García-Barrera T, Gómez-Ariza JL (2014) Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry. J Pharm Biomed Anal 98C: 321-326.
  39. Wood PL, Phillipps A, Woltjer RL, Kaye JA, Quinn JF (2014) Increased lysophosphatidylethanolamine and diacylglycerol levels in Alzheimer’s disease plasma. JSM Alzheimer’s Dis Related Dementia 1: 10001
  40. Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, et al. (2012) Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 287: 2678-2688.
  41. Cheng H, Wang M, Li JL, Cairns NJ, Han X (2013) Specific changes of sulfatide levels in individuals with pre-clinical Alzheimer's disease: an early event in disease pathogenesis. J Neurochem 127: 733-738.
  42. Wood PL, Lawson B, Kaye JA, Quinn JF, Woltjer RL (2014) Shotgun lipidomics of frontal cortex in control, mild cognitive impairment, and Alzheimer’s disease subjects. Acta Neuropsychiatrica (in press).
  43. Lam SM, Wang Y, Duan X, Wenk MR, Kalaria RN, et al. (2014) The brain lipidomes of subcortical ischemic vascular dementia and mixed dementia. Neurobiol Aging 35: 2369-2381.
  44. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, et al. (2011) Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 6: e21643.
  45. Mielke MM, Haughey NJ, RatnamBandaru VV, Schech S, Carrick R, et al. (2010)Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement 6: 378-85.
  46. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y (2012) Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J Lipid Res 53: 567-576.
  47. Popp J, Meichsner S, Kölsch H, Lewczuk P, Maier W, et al. (2013)Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. Biochem Pharmacol 86: 37-42.
  48. Bai Z, Stamova B, Xu H, Ander BP, Wang J, et al. (2014) Distinctive RNA Expression Profiles in Blood Associated With Alzheimer Disease After Accounting for White Matter Hyperintensities in brain . Alzheimer Dis Assoc Disord. 28: 226-233.
  49. Sheinerman KS, Tsivinsky VG, Abdullah L, Crawford F, Umansky SR (2013) Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. Aging (Albany NY) 5: 925-938.
  50. Danborg PB, Simonsen AH, Waldemar G, Heegaard NH (2014) The potential of microRNAs as biofluidmarkers of neurodegenerative diseases - a systematic review. Biomarkers 19: 259-268.